Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: Results from a survey among US cardiologists

Clinical Cardiology

Volumn 37, Issue 2, 2014, Pages 103-107

  Vardi, Moshe ^a,b   Debidda, Marcella ^a   Bhatt, Deepak L ^c,d,e   Mauri, Laura ^a,d,e   Cannon, Christopher P ^a,d,e  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84893958379     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22226     Document Type: Article

References (35)

1. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 52: 676-685.
2. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123: e269-e367.
3. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009; 11: 423-434.
4. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26: 2422-2434. (Pubitemid 41552972)
5. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace. 2007; 9: 1006-1023. (Pubitemid 351773289)
6. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58: e44-e122.
7. Zhao HJ, Zheng ZT, Wang ZH, et al. "Triple therapy" rather than "triple threat": a meta-analysis of the 2 antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest. 2011; 139: 260-270.
8. Gao F, Zhou YJ, Wang ZJ, et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol. 2011; 148: 96-101.
9. Lip GYH, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary-a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010; 31: 1311-1318.
10. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012; 60: 645-681.
11. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-1115.
12. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost. 2011; 106: 569-571.
13. Fauchier L, Pellegrin C, Bernard A, et al. Comparison of frequency of major adverse events in patients with atrial fibrillation receiving bare-metal versus drug-eluting stents in their coronary arteries. Am J Cardiol. 2012; 110: 7-12.
14. Pasceri V, Patti G, Pristipino C, et al. Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. Catheter Cardiovasc Interv. 2010; 75: 936-942.
15. Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011; 4: 522-534.
16. Marin F, Huber K, Lip GY,. Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy. Thromb Haemost. 2013; 110: 623-625.
17. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
18. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339: 1665-1671. (Pubitemid 28550691)
19. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334: 1084-1089. (Pubitemid 26120185)
20. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation. 1998; 98: 1597-1603. (Pubitemid 28500380)
21. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998; 98: 2126-2132. (Pubitemid 28527471)
22. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
23. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
24. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.
25. Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002; 105: 557-563. (Pubitemid 34123428)
26. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013; 127: 634-640.
27. Ruiz-Nodar JM, Marin F, Manzano-Fernandez S, et al. An evaluation of the CHADS(2) stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. Chest. 2011; 139: 1402-1409.
28. Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008; 134: 559-567.
29. Maegdefessel L, Schlitt A, Faerber J, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich). 2008; 103: 628-632.
30. Faxon DP,. How to manage antiplatelet therapy for stenting in a patient requiring oral anticoagulants. Curr Treat Options Cardiovasc Med. 2013; 15: 11-20.
31. Braithwaite D, Emery J, De Lusignan S, et al. Using the Internet to conduct surveys of health professionals: a valid alternative? Fam Pract. 2003; 20: 545-551. (Pubitemid 37258758)
32. Kaplowitz MD, Hadlock TD, Levine R,. A comparison of web and mail survey response rate. Public Opin Q. 2004; 68: 94-101. (Pubitemid 38750629)
33. Kim HL, Hollowell CM, Patel RV, et al. Use of new technology in endourology and laparoscopy by American urologists: internet and postal survey. Urology. 2000; 56: 760-765.
34. Wang TY, Robinson LA, Ou FS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008; 155: 361-368.
35. Valencia J, Mainar V, Bordes P, et al. Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment. J Interv Cardiol. 2008; 21: 218-224. (Pubitemid 351703983)